Cold War tensions and the polio vaccine was the first polio vaccine to receive approval of the U.S. government, and was used until 1961 in America, when the Sabin vaccine was recommended to replace it. Albert Sabin, a virologist who publicly disagreed with Salk and his killed vaccine, worked on creating a vaccine with live, attenuated vaccines. Despite Cold War tensions, in January, 1956 Mikhail Chumakov, the director of Moscow's Polio Research Institute, his wife and colleague Marina Voroshilova, and Anatoli Smorodentsev, traveled to the U.S. in order to study the Salk vaccine and visited the laboratory of Albert Sabin. With the clearance of the FBI, Sabin
Remune P < 0.05 & HIV-1 lymphocyte proliferation P < 0.001 both favoring the Remune Group. The International AIDS Vaccine Research (IAVA) issued a report on “Whole Killed AIDS Vaccines” in 1999 reviewing a diverse aspect of the killed virus approach. Remune Remune is the first therapeutic HIV vaccine based on the killed whole virus approach. Remune was initially invented by Jonas Salk in 1987 and is now being developed by Immune Response BioPharma, Inc. (IRBP) Remune is a therapeutic HIV/AIDS vaccine that has completed over 25 clinical studies to date and shows a robust mechanism of action restoring white blood